Liu J - Search Results

1

Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product.

Seo N, Kuhns S, Andrews DA, Colbert A, Chow V, Liu J. Seo N, et al. Among authors: liu j. Ophthalmol Ther. 2025 Jan;14(1):85-101. doi: 10.1007/s40123-024-01043-5. Epub 2024 Nov 6. Ophthalmol Ther. 2025. PMID: 39503991

2

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab.

Liu J, Eris T, Li C, Cao S, Kuhns S. Liu J, et al. BioDrugs. 2016 Aug;30(4):321-38. doi: 10.1007/s40259-016-0184-3. BioDrugs. 2016. PMID: 27461107 Free PMC article.

3

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.

Seo N, Polozova A, Zhang M, Yates Z, Cao S, Li H, Kuhns S, Maher G, McBride HJ, Liu J. Seo N, et al. Among authors: liu j. MAbs. 2018 May/Jun;10(4):678-691. doi: 10.1080/19420862.2018.1452580. Epub 2018 Apr 20. MAbs. 2018. PMID: 29553864 Free PMC article.

4

Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab.

Sivendran R, Ramírez J, Ramchandani M, Liu J. Sivendran R, et al. Among authors: liu j. Immunotherapy. 2018 Aug;10(11):1011-1021. doi: 10.2217/imt-2018-0040. Epub 2018 Aug 3. Immunotherapy. 2018. PMID: 30071739 Free article. Review.

5

Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab.

Hutterer KM, Polozova A, Kuhns S, McBride HJ, Cao X, Liu J. Hutterer KM, et al. Among authors: liu j. BioDrugs. 2019 Jun;33(3):321-333. doi: 10.1007/s40259-019-00350-9. BioDrugs. 2019. PMID: 30972630 Free PMC article.

6

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.

Markus R, McBride HJ, Ramchandani M, Chow V, Liu J, Mytych D, Fanjiang G. Markus R, et al. Among authors: liu j. Adv Ther. 2019 Aug;36(8):1833-1850. doi: 10.1007/s12325-019-00979-6. Epub 2019 Jun 10. Adv Ther. 2019. PMID: 31183781 Free PMC article. Review.

7

Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product.

Saleem R, Cantin G, Wikström M, Bolton G, Kuhns S, McBride HJ, Liu J. Saleem R, et al. Among authors: liu j. Pharm Res. 2020 May 31;37(6):114. doi: 10.1007/s11095-020-02816-w. Pharm Res. 2020. PMID: 32476063 Free PMC article.

8

Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product.

Seo N, Huang Z, Kuhns S, Sweet H, Cao S, Wikström M, Liu J. Seo N, et al. Among authors: liu j. Biologicals. 2020 Nov;68:79-91. doi: 10.1016/j.biologicals.2020.08.002. Epub 2020 Sep 1. Biologicals. 2020. PMID: 32888776

9

Analytical Similarity Assessment of ABP 959 in Comparison with Eculizumab Reference Product.

Hutterer KM, Ip A, Kuhns S, Cao S, Wikström M, Liu J. Hutterer KM, et al. Among authors: liu j. BioDrugs. 2021 Sep;35(5):563-577. doi: 10.1007/s40259-021-00492-9. Epub 2021 Jul 22. BioDrugs. 2021. PMID: 34296421 Free PMC article.

10

A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar.

Reinisch W, Cohen S, Ramchandani M, Khraishi M, Liu J, Chow V, Franklin J, Colombel JF. Reinisch W, et al. Among authors: liu j. Adv Ther. 2022 Jan;39(1):44-57. doi: 10.1007/s12325-021-01944-y. Epub 2021 Nov 10. Adv Ther. 2022. PMID: 34757601 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

146,857 results

Search Page

Filters